Cytokines and Tumor Immunogenicity

1998 ◽  
pp. 231-247 ◽  
Author(s):  
Federica Cavallo ◽  
Katia Boggio ◽  
Mirella Giovarelli ◽  
Guido Forni
Keyword(s):  
Tumor Immunogenicity

scholarly journals Cyclophilin A Inhibitor Debio-025 Targets Crk, Reduces Metastasis, and Induces Tumor Immunogenicity in Breast Cancer

2020 ◽  
Vol 18 (8) ◽  
pp. 1189-1201
Author(s):  
Viralkumar Davra ◽  
Tamjeed Saleh ◽  
Ke Geng ◽  
Stanley Kimani ◽  
Dhriti Mehta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cyclophilin A ◽  
Tumor Immunogenicity

scholarly journals Synergistic effect of tumor chemo-immunotherapy induced by leukocyte-hitchhiking thermal-sensitive micelles

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Jing Qi ◽  
Feiyang Jin ◽  
Yuchan You ◽  
Yan Du ◽  
Di Liu ◽  
...  
Keyword(s):  
Microwave Irradiation ◽  
Antitumor Immunity ◽  
Chemotherapeutic Drugs ◽  
Chemotherapeutic Drug ◽  
A2a Adenosine Receptor ◽  
Adenosine Receptor Antagonist ◽  
Tumor Immunosuppression ◽  
Tumor Immunogenicity ◽  
Sch 58261 ◽  
Tumor Accumulation

AbstractSome specific chemotherapeutic drugs are able to enhance tumor immunogenicity and facilitate antitumor immunity by inducing immunogenic cell death (ICD). However, tumor immunosuppression induced by the adenosine pathway hampers this effect. In this study, E-selectin-modified thermal-sensitive micelles are designed to co-deliver a chemotherapeutic drug (doxorubicin, DOX) and an A2A adenosine receptor antagonist (SCH 58261), which simultaneously exhibit chemo-immunotherapeutic effects when applied with microwave irradiation. After intravenous injection, the fabricated micelles effectively adhere to the surface of leukocytes in peripheral blood mediated by E-selectin, and thereby hitchhiking with leukocytes to achieve a higher accumulation at the tumor site. Further, local microwave irradiation is applied to induce hyperthermia and accelerates the release rate of drugs from micelles. Rapidly released DOX induces tumor ICD and elicits tumor-specific immunity, while SCH 58261 alleviates immunosuppression caused by the adenosine pathway, further enhancing DOX-induced antitumor immunity. In conclusion, this study presents a strategy to increase the tumor accumulation of drugs by hitchhiking with leukocytes, and the synergistic strategy of chemo-immunotherapy not only effectively arrested primary tumor growth, but also exhibited superior effects in terms of antimetastasis, antirecurrence and antirechallenge.

scholarly journals Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy

Cancers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1468
Author(s):  
Damiënne Marcus ◽  
Relinde I. Y. Lieverse ◽  
Carmen Klein ◽  
Amir Abdollahi ◽  
Philippe Lambin ◽  
...  
Keyword(s):  
Charged Particle ◽  
Clinical Success ◽  
Immune Therapy ◽  
Locally Advanced ◽  
Optimal Dose ◽  
High Energy ◽  
Advanced Lung Cancer ◽  
Antitumor Effects ◽  
Immunological Effects ◽  
Tumor Immunogenicity

Radiotherapy (RT) has been shown to interfere with inflammatory signals and to enhance tumor immunogenicity via, e.g., immunogenic cell death, thereby potentially augmenting the therapeutic efficacy of immunotherapy. Conventional RT consists predominantly of high energy photon beams. Hypofractionated RT regimens administered, e.g., by stereotactic body radiation therapy (SBRT), are increasingly investigated in combination with cancer immunotherapy within clinical trials. Despite intensive preclinical studies, the optimal dose per fraction and dose schemes for elaboration of RT induced immunogenic potential remain inconclusive. Compared to the scenario of combined immune checkpoint inhibition (ICI) and RT, multimodal therapies utilizing other immunotherapy principles such as adoptive transfer of immune cells, vaccination strategies, targeted immune-cytokines and agonists are underrepresented in both preclinical and clinical settings. Despite the clinical success of ICI and RT combination, e.g., prolonging overall survival in locally advanced lung cancer, curative outcomes are still not achieved for most cancer entities studied. Charged particle RT (PRT) has gained interest as it may enhance tumor immunogenicity compared to conventional RT due to its unique biological and physical properties. However, whether PRT in combination with immune therapy will elicit superior antitumor effects both locally and systemically needs to be further investigated. In this review, the immunological effects of RT in the tumor microenvironment are summarized to understand their implications for immunotherapy combinations. Attention will be given to the various immunotherapeutic interventions that have been co-administered with RT so far. Furthermore, the theoretical basis and first evidences supporting a favorable immunogenicity profile of PRT will be examined.

scholarly journals Molecularly targeted photothermal ablation improves tumor specificity and immune modulation in a rat model of hepatocellular carcinoma

2020 ◽  
Vol 3 (1) ◽  
Author(s):  
Nina M. Muñoz ◽  
Crystal Dupuis ◽  
Malea Williams ◽  
Katherine Dixon ◽  
Amanda McWatters ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Indocyanine Green ◽  
Tumor Immunity ◽  
Rat Model ◽  
Thermal Ablation ◽  
Immune Modulation ◽  
Photothermal Ablation ◽  
Profiling Techniques ◽  
Tumor Immunogenicity ◽  
Tumor Specificity

AbstractThermal ablation is a standard therapy for patients with hepatocellular carcinoma (HCC). Contemporary ablation devices are imperfect, as they lack tumor specificity. An ideal ablation modality would generate thermal energy only within tumoral tissue. Furthermore, as hyperthermia is known to influence tumor immunity, such a tumor-specific ablation modality may have the ability to favorably modulate the tumor immune landscape. Here we show a clinically relevant thermal ablation modality that generates tumor-specific hyperthermia, termed molecularly targeted photothermal ablation (MTPA), that is based upon the excellent localization of indocyanine green to HCC. In a syngeneic rat model, we demonstrate the tumor-specific hyperthermia generated by MTPA. We also show through spatial and transcriptomic profiling techniques that MTPA favorably modulates the intratumoral myeloid population towards tumor immunogenicity and diminishes the systemic release of oncogenic cytokines relative to conventional ablation modalities.

Tumor immunogenicity status in high-grade serous ovarian cancer

2021 ◽  
Vol 162 ◽  
pp. S319
Author(s):  
Laurel Berry ◽  
Michael Kelly ◽  
Lance Miller
Keyword(s):  
Ovarian Cancer ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Tumor Immunogenicity

Targeting HLA class I expression to increase tumor immunogenicity

2012 ◽  
Vol 79 (3) ◽  
pp. 147-154 ◽  
Author(s):  
A. B. del Campo ◽  
J. Carretero ◽  
N. Aptsiauri ◽  
F. Garrido
Keyword(s):  
Hla Class I ◽  
Class I ◽  
Tumor Immunogenicity

scholarly journals Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction

eLife ◽  
2019 ◽  
Vol 8 ◽  
Author(s):  
Shixiang Wang ◽  
Zaoke He ◽  
Xuan Wang ◽  
Huimin Li ◽  
Xue-Song Liu
Keyword(s):  
Antigen Presentation ◽  
Antigen Processing ◽  
Checkpoint Inhibitors ◽  
Objective Response ◽  
Unmet Need ◽  
Response Prediction ◽  
Tumor Mutational Burden ◽  
Tumor Immunogenicity ◽  
Improved Performance ◽  
Pan Cancer

Immunotherapy, represented by immune checkpoint inhibitors (ICI), is transforming the treatment of cancer. However, only a small percentage of patients show response to ICI, and there is an unmet need for biomarkers that will identify patients who are more likely to respond to immunotherapy. The fundamental basis for ICI response is the immunogenicity of a tumor, which is primarily determined by tumor antigenicity and antigen presentation efficiency. Here, we propose a method to measure tumor immunogenicity score (TIGS), which combines tumor mutational burden (TMB) and an expression signature of the antigen processing and presenting machinery (APM). In both correlation with pan-cancer ICI objective response rates (ORR) and ICI clinical response prediction for individual patients, TIGS consistently showed improved performance compared to TMB and other known prediction biomarkers for ICI response. This study suggests that TIGS is an effective tumor-inherent biomarker for ICI-response prediction.

scholarly journals Regorafenib in metastatic colorectal cancer: more data for clinical decisions

2021 ◽  
Vol 23 (3) ◽  
pp. 436-441
Author(s):  
Vladislav V. Petkau ◽  
Alisa A. Karimova ◽  
Zinaida V. Akishina
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Tumor Microenvironment ◽  
Metastatic Colorectal Cancer ◽  
Kinase Inhibitor ◽  
Cancer Drug ◽  
Efficacy And Safety ◽  
Tumor Immunogenicity ◽  
Metastatic Activity ◽  
Multiple Kinase Inhibitor

Regorafenib is a multiple kinase inhibitor. It influences/blocks angiogenesis (VEGFR1-3, TIE2), proliferation (KIT, RET, RAF-1, BRAF), metastatic activity (VEGFR2-3, PDGFR), tumor immunogenicity (CSF1R), tumor microenvironment (PDGFR-, PDGFR-, FGFR1-2). Regorafenib has several indications including metastatic colorectal cancer. Efficacy and safety of regorafenib data from clinical trials (CORRECT, CONCUR, CONSIGN) and observational trials from real world (REBECCA, CORRELATE, RECORA, PMS, REGOTAS) are summarized and presented in this issue. State of the matter of molecular-biologic predictors (KRAS, PIK3CA ANG-2, VEGF-A, LDH, CCL5/CCR5, CA 19-9) and radiological predictors (RadioCORRECT and other trials) is highlighted. Regimens with dose modification and its influence on effectiveness and tolerability of regorafenib are described according to the data from ReDOS, RESET, REARRANGE trials. The results from retrospective trials comparing regorafenib and another approved for refractory metastatic colorectal cancer drug trifluridine/tipiracil are presented.

scholarly journals Homeoprotein SIX1 compromises antitumor immunity through TGF-β-mediated regulation of collagens

2021 ◽  
Author(s):  
Wancheng Liu ◽  
Meiling Gao ◽  
Lili Li ◽  
Yu Chen ◽  
Huimin Fan ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Antitumor Immunity ◽  
Immune Cell ◽  
Survival Rates ◽  
Human Tumor ◽  
Cell Infiltration ◽  
Immune Cell Infiltration ◽  
Dependent Manner ◽  
Tumor Immunogenicity ◽  
Collagen Genes

AbstractThe tumor microenvironment (TME), including infiltrated immune cells, is known to play an important role in tumor growth; however, the mechanisms underlying tumor immunogenicity have not been fully elucidated. Here, we discovered an unexpected role for the transcription factor SIX1 in regulating the tumor immune microenvironment. Based on analyses of patient datasets, we found that SIX1 was upregulated in human tumor tissues and that its expression levels were negatively correlated with immune cell infiltration in the TME and the overall survival rates of cancer patients. Deletion of Six1 in cancer cells significantly reduced tumor growth in an immune-dependent manner with enhanced antitumor immunity in the TME. Mechanistically, SIX1 was required for the expression of multiple collagen genes via the TGFBR2-dependent Smad2/3 activation pathway, and collagen deposition in the TME hampered immune cell infiltration and activation. Thus, our study uncovers a crucial role for SIX1 in modulating tumor immunogenicity and provides proof-of-concept evidence for targeting SIX1 in cancer immunotherapy.

Leveraging Epigenetics to Enhance the Cellular Response to Chemotherapies and Improve Tumor Immunogenicity

2018 ◽  
pp. 1-39 ◽  
Author(s):  
Liliya Tyutyunyk-Massey ◽  
Syed U. Haqqani ◽  
Reshma Mandava ◽  
Kirubel Kentiba ◽  
Mallika Dammalapati ◽  
...  
Keyword(s):  
Cellular Response ◽  
Tumor Immunogenicity
Sign in / Sign up

Export Citation Format

Share Document